Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Regeneron Pharmaceuticals (NQ:REGN)

795.10 +11.45 (+1.46%)
Streaming Delayed Price Updated: 10:07 AM EST, Feb 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Regeneron Pharmaceuticals

< Previous 1 2 3 4 5 6 7 8 9
...
59 60 Next >
News headline image
Wall Street Braces for Impact as Delayed Jobs Report Emerges from Data Blackout
New York, NY – November 19, 2025 – Wall Street is on high alert as the highly anticipated September 2025 jobs report, a critical barometer of the nation's economic health, is finally set to be released... 
Via MarketMinute
Topics Artificial Intelligence Bonds Economy
News headline image
Libtayo® (cemiplimab) Approved in the European Union as First and Only Immunotherapy for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma (CSCC) with High Risk of Recurrence after Surgery and Radiation
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Regeneron Pharmaceuticals (NASDAQ:REGN) Screens as a Compelling Value Investment ↗
Regeneron (REGN) appears undervalued with a low P/E ratio, strong profitability, and a rock-solid financial health profile. A compelling value stock. 
Via Chartmill
News headline image
Discover which S&P500 stocks are making waves on Monday. ↗
Let's have a look at what is happening on the US markets one hour before the close of the markets on Monday. Below you can find the top S&P500 gainers and losers in today's session. 
Via Chartmill
News headline image
1 S&P 500 Stock with Exciting Potential and 2 We Question
The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning. Some companies face significant challenges, whether it’s stagnating growth,... 
Via StockStory
Topics Stocks
News headline image
Fear Of An AI Bubble? This Sector Is Quietly Surging While Tech Sinks ↗
While AI stocks slide, healthcare is soaring. XLV leads November gains, outperforming tech as investors rotate. 
Via Benzinga
Topics Artificial Intelligence
News headline image
The Tech Tsunami: How Breakthroughs in AI, Quantum, and Green Energy Are Reshaping the Stock Market
The global financial markets are in the midst of a profound transformation, driven by an accelerating wave of technological advancements. From the intricate algorithms of Artificial Intelligence to the... 
Via MarketMinute
Topics Artificial Intelligence ETFs Economy
News headline image
What's going on in today's session: S&P500 movers ↗
Let's have a look at the top S&P500 gainers and losers one hour before the close of the markets of today's session. 
Via Chartmill
News headline image
Tech Sector Tremors: Is the AI Bubble Deflating, and What's Next for the Market?
As of mid-November 2025, a palpable unease has settled over the technology sector, long the darling of investors and the primary engine of market growth. After a period of unprecedented outperformance,... 
Via MarketMinute
Topics Artificial Intelligence Economy Stocks
News headline image
Wall Street Falls On US Government Reopening Day, Bitcoin Slides To $100,000: What's Moving Markets Thursday? ↗
Risk sentiment deteriorated sharply on Thursday despite federal agencies reopening after the longest government shutdown in U.S. history, as investors aggressively repriced Fed rate-cut expectations... 
Via Benzinga
Topics Economy
News headline image
Explore the top gainers and losers within the S&P500 index in today's session. ↗
Stay updated with the movement of S&P500 stocks in today's session. Discover which S&P500 stocks are making waves on Thursday. 
Via Chartmill
News headline image
Regeneron Highlights Progress at American Society of Hematology (ASH), with Updated Data in Multiple Myeloma, Lymphoma and Paroxysmal Nocturnal Hemoglobinuria Programs
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Here Are the Top Growth Healthcare Stocks Every New Investor Should Know ↗
These top growth stocks have plenty of room left to run. 
Via The Motley Fool
News headline image
CRISPR Therapeutics' Investigational Gene Therapy Shows Promising Lipid-Lowering Effects In Early Trial ↗
CRISPR Therapeutics' CTX310 trial shows strong, sustained lipid reductions and favorable safety, boosting confidence in its gene editing platform. 
Via Benzinga
News headline image
Incyte (NASDAQ:INCY) Q3 Earnings: Leading The Immuno-Oncology Pack
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q3. Today, we are looking at immuno-oncology stocks, starting with... 
Via StockStory
Topics Artificial Intelligence
News headline image
Winners And Losers Of Q3: Regeneron (NASDAQ:REGN) Vs The Rest Of The Immuno-Oncology Stocks
Looking back on immuno-oncology stocks’ Q3 earnings, we examine this quarter’s best and worst performers, including Regeneron (NASDAQ:REGN) and its peers. 
Via StockStory
Topics Artificial Intelligence
News headline image
Merck Takes On Amgen, Regeneron, Lowering Stubbornly High Cholesterol By 60% ↗
Merck said Saturday its new pill — a possible rival to Regeneron and Amgen — lowered high cholesterol by almost 60%. 
Via Investor's Business Daily
News headline image
Phase 2 Trials Demonstrating Antithrombotic Effect of Two Novel Regeneron Factor XI Antibodies Presented at American Heart Association Scientific Sessions and Published in The Lancet
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Dupixent® (dupilumab) Pivotal Trial Met All Primary and Secondary Endpoints, Reducing Signs and Symptoms of Allergic Fungal Rhinosinusitis (AFRS); sBLA Accepted for FDA Priority Review
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Here's How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 20 Years ↗
 
Via Benzinga
News headline image
Looking Into Regeneron Pharmaceuticals Inc's Recent Short Interest ↗
 
Via Benzinga
News headline image
The Shadow of Doubt: Why Investors Are 'Taking Fright' as Markets Brace for Reality
In the dynamic world of finance, where fortunes are made and lost in the blink of an eye, a chilling sentiment has begun to grip investors: the idea that stocks can, indeed, go down. This isn't merely... 
Via MarketMinute
Topics Artificial Intelligence Bonds Economy
News headline image
5 Revealing Analyst Questions From Regeneron’s Q3 Earnings Call
Regeneron’s third quarter results were well received by the market, reflecting strong execution in its commercial portfolio and key products. Management attributed the positive momentum to double-digit... 
Via StockStory
Topics Earnings
News headline image
Michael Burry Is Super-Bearish On Palantir — With 5 Million Puts ↗
Michael Burry's Scion Asset Management filed an updated 13F showing a new large bearish position in Palantir and Nvidia, among others. 
Via Benzinga
News headline image
Regeneron Announces Investor Conference Presentations
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
2 Beaten-Down Stocks That Could Be About to Rally ↗
It would be best to get in before the rest of the market pounces on these opportunities. 
Via The Motley Fool
News headline image
Dupixent® (dupilumab) Wins Prestigious 2025 Prix Galien USA Best Biotechnology Product Award
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
REGN Q3 Deep Dive: Pipeline, Regulatory Progress, and Label Expansion Take Center Stage
Biotech company Regeneron (NASDAQ:REGN) reported Q3 CY2025 results exceeding the market’s revenue expectations, but sales were flat year on year at $3.75 billion. Its non-GAAP profit of $11.83 per... 
Via StockStory
News headline image
Regeneron (REGN) Q3 2025 Earnings Call Transcript ↗
Regeneron (REGN) Q3 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Uncover the latest developments among S&P500 stocks in today's session. ↗
Join us in exploring the top gainers and losers within the S&P500 index one hour before the close of the markets on Tuesday as we examine the latest happenings in today's session. 
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9
...
59 60 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.